NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00291330,Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism,https://clinicaltrials.gov/study/NCT00291330,RE-COVER I,COMPLETED,"The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic venous thromboembolism (VTE), following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication. This trial aims to demonstrate non-inferiority of dabigatran compared with warfarin in patients with acute symptomatic VTE. After achieving non-inferiority, this trial also aims to establish superiority (by means of hierarchical tests) of dabigatran over warfarin.",YES,Thromboembolism,DRUG: dabigatran etexilate 150 mg|DRUG: warfarin (INR 2-3),"Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE, All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)","Number of Participants With Recurrent Symptomatic VTE and All Deaths, VTE or any death which occured from randomisation to end of post treatment period.

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.|Number of Participants With Recurrent Symptomatic DVT, Symptomatic DVT which occured from randomisation to end of post treatment period.

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.|Number of Participants With Recurrent Symptomatic Non-fatal PE, Symptomatic non-fatal PE which occured from randomisation to end of post treatment period.

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.|Number of Participants Who Died Due to VTE, VTE - related deaths which occured from randomisation to end of post treatment period.

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.|Number of Participants Who Died (Any Cause), Any deaths which occured from randomisation to end of post treatment period. All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., For statistical analysis 1: from randomisation to 6 months (up to day 180) For statistical analysis 2: from randomisation to end of ptp, planned to be up to day 224.|Number of Participants With Bleeding Events, Major bleeding events (MBE) were defined as

* Fatal bleeding
* Symptomatic bleeding in a critical area or organ
* Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells

Clinically-relevant bleeding events (CRBE) was defined as

* spontaneous skin hematoma \>=25 cm²
* spontaneous nose bleed \>5 min
* macroscopic hematuria spontaneous or \>24 hours if associated with an intervention
* spontaneous rectal bleeding (more than spotting on toilet paper)
* gingival bleeding \>5 min
* leading to hospitalisation and / or requiring surgical treatment
* leading to a transfusion of \<2 units of whole blood or red cells
* any other bleeding event considered clinically relevant by the investigator

Any bleeding events were defined as major, clinically-relevant and nuisance bleeding events. Nuisance bleeding events were defined as all other bleeding events that did not fulfil the criteria from above., From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)|Number of Participants With Acute Coronary Syndrome (ACS), Any ACS occurring during the conduct of the study (centrally adjudicated as definite).

Counts of patients having a centrally adjudicated definite ACS during intake of active study drug, after stopping active study drug and before or without intake of active study drug, according to treatment group.

All suspected recurrent VTEs and all deaths and bleeding events were evaluated by an independent central adjudication committee, and all analyses are based on the events that were centrally confirmed by this committee., From first intake of study drug to end of study conduct|Laboratory Analyses, Frequency of patients with possible clinically significant abnormalities., From first intake of study drug to last intake of study drug + 6 days washout (washout time can be reduced until 0 day if the patient takes an other anti-coagulant therapy on and after last intake of active study drug)",,Boehringer Ingelheim,,ALL,"ADULT, OLDER_ADULT",PHASE3,2564,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,1160.53|2005-001999-12,2006-02,2009-05,,2006-02-14,2011-02-11,2014-06-06,"1160.53.01035 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|1160.53.01056 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States|1160.53.01044 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States|1160.53.01033 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States|1160.53.01046 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States|1160.53.01019 Boehringer Ingelheim Investigational Site, Augusta, Georgia, United States|1160.53.01008 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States|1160.53.01010 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States|1160.53.01014 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|1160.53.01023 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|1160.53.01029 Boehringer Ingelheim Investigational Site, Pontiac, Michigan, United States|1160.53.01009 Boehringer Ingelheim Investigational Site, St. Louis Park, Minnesota, United States|1160.53.01031 Boehringer Ingelheim Investigational Site, Lebanon, New Hampshire, United States|1160.53.01036 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States|1160.53.01025 Boehringer Ingelheim Investigational Site, Valhalla, New York, United States|1160.53.01027 Boehringer Ingelheim Investigational Site, Chapel Hill, North Carolina, United States|1160.53.01039 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|1160.53.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States|1160.53.01013 Boehringer Ingelheim Investigational Site, Toledo, Ohio, United States|1160.53.01028 Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|1160.53.01052 Boehringer Ingelheim Investigational Site, Altoona, Pennsylvania, United States|1160.53.01055 Boehringer Ingelheim Investigational Site, Summerville, South Carolina, United States|1160.53.01017 Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States|1160.53.54017 Boehringer Ingelheim Investigational Site, Adrogué, Argentina|1160.53.54003 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1160.53.54005 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1160.53.54006 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1160.53.54007 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1160.53.54010 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina|1160.53.61002 Boehringer Ingelheim Investigational Site, Woolloongabba, Queensland, Australia|1160.53.61004 Boehringer Ingelheim Investigational Site, Bedford Park, South Australia, Australia|1160.53.61003 Boehringer Ingelheim Investigational Site, Box Hill, Victoria, Australia|1160.53.61001 Boehringer Ingelheim Investigational Site, Clayton, Victoria, Australia|1160.53.61006 The Avenue Cardiovascular Centre, Windsor, Victoria, Australia|1160.53.61005 Boehringer Ingelheim Investigational Site, Perth, Western Australia, Australia|1160.53.43001 Boehringer Ingelheim Investigational Site, Graz, Austria|1160.53.43003 Boehringer Ingelheim Investigational Site, Innsbruck, Austria|1160.53.43002 Boehringer Ingelheim Investigational Site, Wien, Austria|1160.53.32003 Boehringer Ingelheim Investigational Site, Brussel, Belgium|1160.53.32001 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1160.53.32002 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1160.53.32007 Boehringer Ingelheim Investigational Site, Edegem, Belgium|1160.53.32005 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1160.53.32004 Boehringer Ingelheim Investigational Site, Liège, Belgium|1160.53.55010 Boehringer Ingelheim Investigational Site, Brasília, Brazil|1160.53.55007 Boehringer Ingelheim Investigational Site, Campinas, Brazil|1160.53.55001 Boehringer Ingelheim Investigational Site, Cerqueira César - Sao Paulo, Brazil|1160.53.55002 Boehringer Ingelheim Investigational Site, Cerqueira César - São Paulo, Brazil|1160.53.55014 Boehringer Ingelheim Investigational Site, Cristo Rei - Curitiba, Brazil|1160.53.55011 Boehringer Ingelheim Investigational Site, Goiânia -, Brazil|1160.53.55017 Boehringer Ingelheim Investigational Site, Paraná -, Brazil|1160.53.55012 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|1160.53.55016 Boehringer Ingelheim Investigational Site, Rio de Janeiro - RJ, Brazil|1160.53.55004 Boehringer Ingelheim Investigational Site, Santo André, Brazil|1160.53.55005 Boehringer Ingelheim Investigational Site, São José do Rio Preto, Brazil|1160.53.02006 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada|1160.53.02013 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada|1160.53.02021 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada|1160.53.02004 Boehringer Ingelheim Investigational Site, Saint Johns, New Brunswick, Canada|1160.53.02001 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|1160.53.02002 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1160.53.02005 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1160.53.02010 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1160.53.02022 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1160.53.02011 Boehringer Ingelheim Investigational Site, London, Ontario, Canada|1160.53.02015 Boehringer Ingelheim Investigational Site, Ottawa, Ontario, Canada|1160.53.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1160.53.02008 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1160.53.02009 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1160.53.02014 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1160.53.02017 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1160.53.02003 Boehringer Ingelheim Investigational Site, Sainte-Foy, Quebec, Canada|1160.53.02020 Boehringer Ingelheim Investigational Site, Quebec, Canada|1160.53.42001 Boehringer Ingelheim Investigational Site, Brno, Czech Republic|1160.53.42002 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czech Republic|1160.53.42011 Boehringer Ingelheim Investigational Site, Hranice, Czech Republic|1160.53.42009 Boehringer Ingelheim Investigational Site, Jihlava, Czech Republic|1160.53.42012 Boehringer Ingelheim Investigational Site, Liberec, Czech Republic|1160.53.42015 Boehringer Ingelheim Investigational Site, Novy Jicin, Czech Republic|1160.53.42005 Boehringer Ingelheim Investigational Site, Ostrava-Vitkovice, Czech Republic|1160.53.42004 Boehringer Ingelheim Investigational Site, Praha 2, Czech Republic|1160.53.42014 Boehringer Ingelheim Investigational Site, Tabor, Czech Republic|1160.53.42016 Boehringer Ingelheim Investigational Site, Teplice, Czech Republic|1160.53.42010 Boehringer Ingelheim Investigational Site, Usti nad Labem, Czech Republic|1160.53.42007 Boehringer Ingelheim Investigational Site, Zlin, Czech Republic|1160.53.45008 Boehringer Ingelheim Investigational Site, Esbjerg, Denmark|1160.53.45009 Boehringer Ingelheim Investigational Site, Holbæk, Denmark|1160.53.45002 Boehringer Ingelheim Investigational Site, Kolding, Denmark|1160.53.45004 Boehringer Ingelheim Investigational Site, København NV, Denmark|1160.53.45007 Boehringer Ingelheim Investigational Site, København S, Denmark|1160.53.45006 Boehringer Ingelheim Investigational Site, Slagelse, Denmark|1160.53.3301A Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301B Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301C Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301D Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301E Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301F Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301H Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3301I Boehringer Ingelheim Investigational Site, Brest Cedex, France|1160.53.3302A Boehringer Ingelheim Investigational Site, Lorient, France|1160.53.3310A Boehringer Ingelheim Investigational Site, Montpellier Cedex 5, France|1160.53.3310B Boehringer Ingelheim Investigational Site, Montpellier Cedex 5, France|1160.53.3310C Boehringer Ingelheim Investigational Site, Montpellier Cedex 5, France|1160.53.3308B Boehringer Ingelheim Investigational Site, Nancy, France|1160.53.3303B Boehringer Ingelheim Investigational Site, St Etienne Cedex 2, France|1160.53.3303C Boehringer Ingelheim Investigational Site, St Etienne Cedex 2, France|1160.53.3303D Boehringer Ingelheim Investigational Site, St Etienne Cedex 2, France|1160.53.3303E Boehringer Ingelheim Investigational Site, St Etienne Cedex 2, France|1160.53.3303A Boehringer Ingelheim Investigational Site, St Priest en Jarez, France|1160.53.3311A Boehringer Ingelheim Investigational Site, Toulon Naval, France|1160.53.3311B Boehringer Ingelheim Investigational Site, Toulon Naval, France|1160.53.3311C Boehringer Ingelheim Investigational Site, Toulon Naval, France|1160.53.3311D Boehringer Ingelheim Investigational Site, Toulon Naval, France|1160.53.3311E Boehringer Ingelheim Investigational Site, Toulon Naval, France|1160.53.3308A Boehringer Ingelheim Investigational Site, Vandoeuvre les Nancy, France|1160.53.49017 Boehringer Ingelheim Investigational Site, Dresden, Germany|1160.53.49018 Boehringer Ingelheim Investigational Site, Dresden, Germany|1160.53.49003 Boehringer Ingelheim Investigational Site, Köln, Germany|1160.53.49005 Boehringer Ingelheim Investigational Site, Mannheim, Germany|1160.53.49007 Boehringer Ingelheim Investigational Site, München, Germany|1160.53.49009 Boehringer Ingelheim Investigational Site, Püttlingen, Germany|1160.53.30001 Boehringer Ingelheim Investigational Site, Athens, Greece|1160.53.30005 Boehringer Ingelheim Investigational Site, Athens, Greece|1160.53.30006 Boehringer Ingelheim Investigational Site, Athens, Greece|1160.53.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1160.53.36006 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1160.53.36002 Boehringer Ingelheim Investigational Site, Debrecen, Hungary|1160.53.36013 Boehringer Ingelheim Investigational Site, Eger, Hungary|1160.53.36012 Boehringer Ingelheim Investigational Site, Gyula, Hungary|1160.53.36004 Boehringer Ingelheim Investigational Site, Miskolc, Hungary|1160.53.36003 Boehringer Ingelheim Investigational Site, Pecs, Hungary|1160.53.36011 Boehringer Ingelheim Investigational Site, Szombathely, Hungary|1160.53.36010 Boehringer Ingelheim Investigational Site, Székesfehérvár, Hungary|1160.53.91011 Boehringer Ingelheim Investigational Site, Bangalore, India|1160.53.91012 Boehringer Ingelheim Investigational Site, Chennai, India|1160.53.91019 Boehringer Ingelheim Investigational Site, Chennai, India|1160.53.91013 Boehringer Ingelheim Investigational Site, Indore, India|1160.53.91021 Boehringer Ingelheim Investigational Site, Karna, India|1160.53.91022 Boehringer Ingelheim Investigational Site, Kerala, India|1160.53.91020 Boehringer Ingelheim Investigational Site, Ludhiana, India|1160.53.91007 Boehringer Ingelheim Investigational Site, Mysore, India|1160.53.91015 Boehringer Ingelheim Investigational Site, Nagpur, India|1160.53.91010 Boehringer Ingelheim Investigational Site, New Delhi, India|1160.53.91005 Boehringer Ingelheim Investigational Site, Pune, India|1160.53.91008 Boehringer Ingelheim Investigational Site, Pune, India|1160.53.91004 Boehringer Ingelheim Investigational Site, Vadodara, India|1160.53.97202 Boehringer Ingelheim Investigational Site, Afula, Israel|1160.53.97207 Boehringer Ingelheim Investigational Site, Ashkelon, Israel|1160.53.97211 Boehringer Ingelheim Investigational Site, Haifa, Israel|1160.53.97203 Boehringer Ingelheim Investigational Site, Holon, Israel|1160.53.97205 Boehringer Ingelheim Investigational Site, KfarSaba, Israel|1160.53.97206 Boehringer Ingelheim Investigational Site, Petah Tiqwa, Israel|1160.53.97204 Boehringer Ingelheim Investigational Site, Tel Hashomer, Israel|1160.53.97210 Boehringer Ingelheim Investigational Site, Tel-Aviv, Israel|1160.53.97201 Boehringer Ingelheim Investigational Site, Zerifin, Israel|1160.53.39003 Boehringer Ingelheim Investigational Site, Bologna, Italy|1160.53.39002 Boehringer Ingelheim Investigational Site, Padova, Italy|1160.53.39001 Boehringer Ingelheim Investigational Site, Perugia, Italy|1160.53.39004 Boehringer Ingelheim Investigational Site, Reggio Emilia, Italy|1160.53.39007 Boehringer Ingelheim Investigational Site, Vimercate, Italy|1160.53.39005 Boehringer Ingelheim Investigational Site, Vittorio Veneto (tv), Italy|1160.53.5264 Boehringer Ingelheim Investigational Site, Chihuahua, Mexico|1160.53.5270 Boehringer Ingelheim Investigational Site, Culiacan, Mexico|1160.53.5262 Boehringer Ingelheim Investigational Site, San Luis Potosí, Mexico|1160.53.31010 Boehringer Ingelheim Investigational Site, 's Hertogenbosch, Netherlands|1160.53.31001 Boehringer Ingelheim Investigational Site, Amersfoort, Netherlands|1160.53.31006 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1160.53.31013 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands|1160.53.31005 Boehringer Ingelheim Investigational Site, Maastricht, Netherlands|1160.53.31002 Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands|1160.53.31004 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|1160.53.31009 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|1160.53.64003 Boehringer Ingelheim Investigational Site, Auckland, New Zealand|1160.53.64004 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand|1160.53.64002 Boehringer Ingelheim Investigational Site, Otahuhu Auckland, New Zealand|1160.53.64001 Boehringer Ingelheim Investigational Site, Takapuna Auckland, New Zealand|1160.53.47001 Boehringer Ingelheim Investigational Site, Oslo, Norway|1160.53.47004 Boehringer Ingelheim Investigational Site, Oslo, Norway|1160.53.47003 Boehringer Ingelheim Investigational Site, Rud, Norway|1160.53.47005 Boehringer Ingelheim Investigational Site, Trondheim, Norway|1160.53.35104 Boehringer Ingelheim Investigational Site, Almada, Portugal|1160.53.35109 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|1160.53.35101 Boehringer Ingelheim Investigational Site, Lisboa, Portugal|1160.53.35102 Boehringer Ingelheim Investigational Site, Lisboa, Portugal|1160.53.35105 Boehringer Ingelheim Investigational Site, Lisboa, Portugal|1160.53.07011 Boehringer Ingelheim Investigational Site, Chelyabinsk, Russian Federation|1160.53.07021 Boehringer Ingelheim Investigational Site, Chelyabinsk, Russian Federation|1160.53.07007 Boehringer Ingelheim Investigational Site, Ekaterinburg, Russian Federation|1160.53.07016 Boehringer Ingelheim Investigational Site, Krasnodar, Russian Federation|1160.53.07004 Boehringer Ingelheim Investigational Site, Kursk, Russian Federation|1160.53.07003 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1160.53.07010 Boehringer Ingelheim Investigational Site, Novosibirsk, Russian Federation|1160.53.07020 Boehringer Ingelheim Investigational Site, Omsk, Russian Federation|1160.53.07018 Boehringer Ingelheim Investigational Site, Pskov, Russian Federation|1160.53.07009 Boehringer Ingelheim Investigational Site, Rostov-na-Donu, Russian Federation|1160.53.07023 Boehringer Ingelheim Investigational Site, Rostov-na-Donu, Russian Federation|1160.53.07024 Boehringer Ingelheim Investigational Site, Rostov-na-Donu, Russian Federation|1160.53.07025 Boehringer Ingelheim Investigational Site, Rostov-na-Donu, Russian Federation|1160.53.07001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1160.53.07014 Boehringer Ingelheim Investigational Site, Ufa, Russian Federation|1160.53.07005 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|1160.53.07006 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|1160.53.42107 Boehringer Ingelheim Investigational Site, Banska Bystrica, Slovakia|1160.53.42106 Boehringer Ingelheim Investigational Site, Lucenec, Slovakia|1160.53.42102 Boehringer Ingelheim Investigational Site, Nitra, Slovakia|1160.53.42103 Boehringer Ingelheim Investigational Site, Nove Zamky, Slovakia|1160.53.42104 Boehringer Ingelheim Investigational Site, Zilina, Slovakia|1160.53.27007 Boehringer Ingelheim Investigational Site, Centurion, South Africa|1160.53.27001 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|1160.53.27002 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|1160.53.27004 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|1160.53.27006 Boehringer Ingelheim Investigational Site, Johannesburg, South Africa|1160.53.27009 Suite 404, Medical Centre, Pretoria, South Africa|1160.53.27003 Boehringer Ingelheim Investigational Site, Randburg, South Africa|1160.53.27008 Suite M5, Second Floor, Richards Bay, South Africa|1160.53.27005 Boehringer Ingelheim Investigational Site, Roodepoort, South Africa|1160.53.34012 Boehringer Ingelheim Investigational Site, Badalona (Barcelona), Spain|1160.53.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1160.53.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1160.53.34007 Boehringer Ingelheim Investigational Site, Cartagena. Murcia, Spain|1160.53.34003 Boehringer Ingelheim Investigational Site, Cuenca, Spain|1160.53.34009 Boehringer Ingelheim Investigational Site, Madrid, Spain|1160.53.34010 Boehringer Ingelheim Investigational Site, Madrid, Spain|1160.53.34004 Boehringer Ingelheim Investigational Site, Santander, Spain|1160.53.34005 Boehringer Ingelheim Investigational Site, Torrelavega.Santander, Spain|1160.53.34011 Boehringer Ingelheim Investigational Site, Valencia, Spain|1160.53.46002 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1160.53.46006 Boehringer Ingelheim Investigational Site, Jönköping, Sweden|1160.53.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1160.53.46007 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1160.53.46008 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1160.53.46005 Boehringer Ingelheim Investigational Site, Sundsvall, Sweden|1160.53.46003 Boehringer Ingelheim Investigational Site, Uppsala, Sweden|1160.53.90003 Boehringer Ingelheim Investigational Site, Ankara, Turkey|1160.53.90004 Boehringer Ingelheim Investigational Site, Ankara, Turkey|1160.53.90005 Boehringer Ingelheim Investigational Site, Ankara, Turkey|1160.53.90001 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|1160.53.90002 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|1160.53.90007 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|1160.53.90006 Boehringer Ingelheim Investigational Site, Izmir, Turkey|1160.53.38006 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1160.53.38005 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine|1160.53.38003 Boehringer Ingelheim Investigational Site, Zaporozhye, Ukraine|1160.53.44008 Boehringer Ingelheim Investigational Site, Aberdeen, United Kingdom|1160.53.44005 Boehringer Ingelheim Investigational Site, Headington, Oxford, United Kingdom|1160.53.44004 Boehringer Ingelheim Investigational Site, London, United Kingdom|1160.53.44009 Boehringer Ingelheim Investigational Site, London, United Kingdom|1160.53.44011 Boehringer Ingelheim Investigational Site, London, United Kingdom|1160.53.44006 Boehringer Ingelheim Investigational Site, Newcastle upon Tyne, United Kingdom|1160.53.44012 Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom",
